- Home
- CCM vs IGC Comparison
CCM vs IGC Comparison
Compare CCM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCM | IGC |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 28.5M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCM | IGC |
|---|---|---|
| Price | $4.52 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 12.0K | ★ 465.2K |
| Earning Date | 09-26-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,056,841.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $0.25 |
| 52 Week High | $10.77 | $0.50 |
Technical Indicators
Market Signals| Indicator | CCM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 46.13 |
| Support Level | $4.08 | $0.29 |
| Resistance Level | $5.40 | $0.31 |
| Average True Range (ATR) | 0.61 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 31.25 | 37.71 |
Price Performance
Historical ComparisonAbout CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.